Good Governance for Medicines

Democratisation of Medicines

As medicines are the most common health intervention, HAI Europe firmly believes that pharmaceutical policies should address wide public health needs. Our exclusive focus on policy analysis provides us with a unique perspective amongst European health stakeholders. HAI Europe’s campaigns aim to ensure that EU policies and decision-making align with societal interests, preventing commercial interests from overriding the interests of public health.

News

24 Nov 2011 – Too few checks are being made on ex-Commission officials who move into jobs in the lobby industry, resulting in abuses of power, according to a new report published today by the ALTER-EU. The report “Block the Revolving Door: Why we need to stop EU officials from becoming lobbyists” profiles 15 cases including Thomas Lonngren who moved to a pharmaceutical industry consultancy within weeks of leaving his post as Executive Director of the European Medicines Agency.

Policy Briefs & Reports

The patient & consumer voice and pharmaceutical industry sponsorship establishes a link between the opinions of advocacy groups on EU medicines policies and the funding they receive from the drug industry. Read more

Patient & consumer organisations at the EMA: Financial disclosure & transparency

A survey of advocacy organisations at the EMA reveals the ineffectiveness of the Agency's transparency criteria. Read more